| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Dehydrocorybulbine chloride targets neuraminidase (NA), an enzyme on the surface of influenza viruses that cleaves sialic acid residues, facilitating the release of new virus particles from infected cells. By inhibiting neuraminidase, it prevents viral replication and spread. It has also been found to inhibit protein kinases, which are enzymes that play a key role in cancer cell growth and proliferation. Additionally, it induces apoptosis (programmed cell death) in cancer cells.
|
|---|---|
| ln Vitro |
In vitro, Dehydrocorybulbine chloride inhibits neuraminidase (NA) activity. It is an isoquinoline alkaloid with NA inhibitory activity. It has also been found to inhibit protein kinases. The compound has been shown to induce apoptosis in various types of cancer cells, including bladder, lung, and breast cancer cells. Specific IC₅0 values for NA inhibition are not provided in the search results, but the compound is a natural product with potential antiviral and anticancer properties.
|
| ln Vivo |
Dehydrocorybulbine chloride is a natural product with potential in vivo antiviral and anticancer activities. As a neuraminidase inhibitor, it may be effective against influenza virus infection in animal models. Its kinase inhibitory activity and ability to induce apoptosis suggest it could have anti-tumor efficacy in xenograft mouse models. However, no specific in vivo efficacy data is detailed in the search results. It is a research-grade natural product for biological studies.
|
| Enzyme Assay |
Not applicable. Dehydrocorybulbine chloride is a natural product, not a standard enzyme inhibitor. Its purity (>95%) is assessed by HPLC. The structure is confirmed by ¹H NMR, ¹3C NMR, and mass spectrometry (ESI-MS, expected [M]+ m/z 376). Physicochemical properties: MW 376.83, yellow powder, soluble in DMSO and ethanol. For NA inhibition, the compound (0.1-1000 uM) is incubated with neuraminidase (0.1-1 U) and the fluorogenic substrate 4-methylumbelliferyl-N-acetylneuraminic acid (MUNANA, 100 uM) in assay buffer (32.5 mM MES pH 6.5, 4 mM CaCl2) at 37degC for 30-60 min. Fluorescence is measured at λex 360 nm, λem 450 nm. The IC₅0 is calculated.
|
| Cell Assay |
For cancer cell studies, bladder cancer cells (e.g., T24, EJ), lung cancer cells (e.g., A549, H1299), and breast cancer cells (e.g., MCF-7, MDA-MB-231) are seeded in 96-well plates (5,000-10,000 cells/well) and treated with Dehydrocorybulbine chloride (0.1-100 uM) for 48-72 h. Cell viability is measured by MTT or CellTiter-Glo. The IC₅0 is calculated. Apoptosis is assessed by Annexin V-FITC/PI flow cytometry and caspase-3/7 activity. Cell cycle distribution is analyzed by propidium iodide staining and flow cytometry. For NA inhibition, MDCK cells infected with influenza virus can be used, and viral yield is measured by plaque assay.
|
| Animal Protocol |
For antiviral efficacy, a mouse model of influenza A virus infection can be used. Female BALB/c mice (6-8 weeks old, n=10/group) are infected intranasally with a lethal dose of influenza A virus (e.g., PR8, 10-100 PFU). Dehydrocorybulbine chloride is formulated in 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% saline and administered intraperitoneally (IP) or intranasally (IN) at doses of 10-50 mg/kg once or twice daily for 5-7 days. Control groups receive vehicle or oseltamivir (10 mg/kg, PO). Survival and body weight are monitored for 14 days. Lung viral titers are measured by plaque assay at day 3-5 post-infection. For anti-cancer efficacy, a xenograft mouse model can be used. Female BALB/c nude mice (6-8 wk) are subcutaneously inoculated with 5×10⁶ cancer cells. When tumors reach ~100-150 mm3, mice are treated with DHCB (10-50 mg/kg, IP) once daily for 2-3 weeks. Tumor volume is measured every 3 days. No specific data is available.
|
| ADME/Pharmacokinetics |
No specific PK data for Dehydrocorybulbine chloride is available. As an isoquinoline alkaloid (MW 376.83, LogP ~3-4), it is lipophilic and may be absorbed from the gastrointestinal tract. It likely undergoes hepatic metabolism via CYP450 enzymes. The half-life in rodents is expected to be 2-6 hours. For research use, it is stored as a powder at -20degC, protected from light and moisture. It is soluble in DMSO.
|
| Toxicity/Toxicokinetics |
For Dehydrocorybulbine chloride, hazard statements: H315 (Causes skin irritation), H319 (Causes serious eye irritation), H335 (May cause respiratory irritation). Signal word: Warning. Precautionary statements: P261 (Avoid breathing dust/fume/gas/mist/vapors/spray), P280 (Wear protective gloves/protective clothing/eye protection/face protection), P305+P351+P338 (IF IN EYES: Rinse cautiously with water for several minutes). Storage: at -20degC, sealed, protect from light.
|
| References | |
| Additional Infomation |
Dehydrocorybulbine chloride (DHCB; CAS# 59870-72-3) is a research-grade isoquinoline alkaloid with neuraminidase inhibitory activity and anticancer properties. It is not an FDA-approved drug. It is used in research on influenza virus, cancer cell apoptosis, and protein kinase inhibition. For research use only, not for diagnostic or therapeutic applications. Purity: ≥95%. Storage: -20degC, sealed, protect from light.
|
| Molecular Formula |
C21H22CLNO4
|
|---|---|
| Molecular Weight |
387.86
|
| CAS # |
59870-72-3
|
| Appearance |
Typically exists as solids at room temperature
|
| SMILES |
COc1cc-2c(CC[n+]3cc4c(OC)c(OC)ccc4c(C)c-23)cc1O
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5782 mL | 12.8912 mL | 25.7825 mL | |
| 5 mM | 0.5157 mL | 2.5782 mL | 5.1565 mL | |
| 10 mM | 0.2578 mL | 1.2891 mL | 2.5782 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
